Dear Kevin

Anonymous

Guest
To be clear, you should retire and here is why.

First, you have more than enough money. You could easily spend the rest of your days enjoying yourself doing whatever it is you want to do - somewhere else. If it truly is serving patients, you could volunteer at a hospital or maybe even donate some of your vast wealth you gained from them.

Second, the stock is in the crapper. Wall street would rejoice on news of your departure because like it or not you have the job that is responsible for increasing shareholder (not Sharer) value. In this you have failed. It is true and you cannot possible make a valid argument otherwise.

Thirdly, belt tightening should be lead by example. If you left, Amgen could pay a new CEO a reasonable salary without the ridiculous perquisites. That would be quite a bit of savings and we would have the added benefit of not being embarrassed by you flying around in a private jet funded by people with grievous illnesses.

Seriously, you should retire.
 
























I think if Kevin has some type of self respect, he should resign, his leadership is questionable. After all, if you have spend over ten years in a company with such of poor return,the least you should do is leave and allow a company that was a great place to work the change to become what it was.
 






BENTONVILLE, Ark., Aug. 7 /PRNewswire-FirstCall/ -- Wal-Mart Stores,
Inc. is pleased to announce that Dr. John Agwunobi, current Assistant
Secretary for Health for the U.S. Department of Health and Human Services
and an Admiral in the U.S. Public Health Service Commissioned Corps, has
been named Senior Vice President and President for the Professional
Services Division for Wal-Mart in the U.S. effective September 4.
Dr. Agwunobi will oversee the company's health and wellness business
unit including pharmacies, vision centers and health care clinics. He is
the country's expert on public health, and he will bring new perspective,
diverse talents and tremendous expertise to our company in his new role.
He will report to Bill Simon, executive vice president and chief
operating officer for Wal-Mart Stores U.S.
"John is the country's expert on public health, and I look forward to
his contributions in furthering Wal-Mart's health and wellness efforts,"
said Simon. "He will bring new perspective, diverse talents and tremendous
expertise to our company in his new role." Added Dr. Agwunobi, "Wal-Mart
touches many lives in many communities and this position provides me with a
new opportunity to reach people in the places where they live, work and
shop. I am very excited to join the Wal-Mart team."
Dr. Agwunobi, also a pediatrician, is a seasoned public health
professional with experience in health care delivery, managed care and
health care policy. As Assistant Secretary for Health, he was responsible
for disease prevention, health promotion, women and minority health
efforts, the reduction of health disparities, the fight against HIV/AIDS,
pandemic influenza planning and vaccine preventable disease initiatives.
Prior to his current position, Dr. Agwunobi served as Florida's
Secretary of Health and State Health Officer from October 2001 to September
2005. In this role, he confronted many public health challenges, including
leading the state's public health and medical response to four major
hurricanes, led the call for a healthier Florida, managed the response to
the nation's first-ever intentional anthrax attack, and guided Florida's
nationally-recognized efforts to protect the state against bioterrorism.
Wal-Mart Stores, Inc. operates Wal-Mart discount stores, supercenters,
Neighborhood Markets and Sam's Club locations in the United States. The
Company operates in Argentina, Brazil, Canada, China, Costa Rica, El
Salvador, Guatemala, Honduras, Japan, Mexico, Nicaragua, Puerto Rico and
the United Kingdom. The Company's common stock is listed on the New York
Stock Exchange under the symbol WMT. More information about Wal-Mart can be
found by visiting http://www.walmartstores.com. Online merchandise sales
are available at http://www.walmart.com and http://www.samsclub.com.
 






Mr. David W. Beier is Senior Vice President - Global Government and Corporate Affairs of Amgen Inc since March 2008. He joined the Company in 2003 as Senior Vice President, Global Government Affairs. Previously, Mr. Beier was a partner with the law firm of Hogan and Hartson in Washington, D.C. From 1998 to early 2001, Mr. Beier served as Chief Domestic Policy Advisor to the Vice President of the United States. He also held positions as Vice President of Government Affairs and Public Policy for Genentech and staff counsel in the U.S. House of Representatives. Mr. Beier is a director of ARYx Therapeutics, Inc.
 
























Don't be in too much of a hurry. Mr. Sharer will retire on his 65th birthday, which is about a year and a half from now.

I think Bob Bradway will then take over as the new CEO.

He is another one of Kevin's boys. Would not make a difference. This company needs new blood and needs it quickly. Kevin has virtually killed it.
 












with epo revenue on the decline and patent expiration around the bend, a lousy pipeline, prolia DOA, den of thieves occupying corner offices, borrowing money to pay for the new dividend, this company is in short, a shell game. After 11 years of dead money, there will be no more knife catchers this time to prop up this cow chip
 






It should be obvious by now that only people in the last ten years who have benefited from Sharer's reign are Kevin himself and his cronies. This should become a textbook example of how to take take a highly innovative growth company and turn it into a stodgy old clunker in less than ten years. Pathetic.
 






Key Findings
FDA enforcement actions have declined under the Bush
Administration.

The number of warning letters issued by the agency for violations of federal requirements has fallen by over 50%, from 1,154 in 2000 to 535 in 2005, a 15- year low. During the same period, the number of seizures of mislabeled, defective, and dangerous products has declined by
44%. Every center within FDA has experienced a decline in enforcement.

The decline in enforcement does not appear to be the result of increased compliance by
Manufacturers. The number of violations by food and drug manufacturers observed by FDA agents during field inspections has remained relatively constant.

At the request of Rep. Henry A. Waxman (2006), this report examines how the Bush Administration has carried out FDA’s historic enforcement responsibilities. The report is the result of a 15-month investigation that included a review of thousands of pages of internal agency enforcement records.
 












Dear Kevin,

We are placing you (Kevin Sharer) on a PIP. If you don't turn the stock around (get it above $60/share by the 4th quarter earnings call) you will be considered in violation of the terms of this plan and will be terminated. (WE ALL WISH!!)